Lannett Company, Inc. (LCI) Expected to Post Quarterly Sales of $146.48 Million
Analysts predict that Lannett Company, Inc. (NYSE:LCI) will announce sales of $146.48 million for the current quarter, Zacks reports. Two analysts have provided estimates for Lannett’s earnings, with the highest sales estimate coming in at $147.80 million and the lowest estimate coming in at $145.15 million. Lannett reported sales of $154.96 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 5.5%. The business is scheduled to report its next quarterly earnings results on Monday, November 5th.
On average, analysts expect that Lannett will report full-year sales of $602.13 million for the current financial year, with estimates ranging from $600.06 million to $604.20 million. For the next year, analysts expect that the company will post sales of $501.38 million, with estimates ranging from $500.75 million to $502.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Lannett.
Lannett (NYSE:LCI) last announced its quarterly earnings data on Tuesday, August 28th. The company reported $0.64 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.64. Lannett had a net margin of 4.19% and a return on equity of 19.92%. The business had revenue of $170.90 million for the quarter, compared to analyst estimates of $171.21 million. During the same period last year, the business earned $0.40 EPS. The company’s revenue was up 22.9% on a year-over-year basis.
Shares of LCI opened at $4.03 on Friday. Lannett has a twelve month low of $3.35 and a twelve month high of $30.35. The firm has a market capitalization of $184.78 million, a PE ratio of 1.30 and a beta of 1.93. The company has a current ratio of 2.62, a quick ratio of 1.92 and a debt-to-equity ratio of 1.29.
In related news, Director Patrick G. Lepore bought 25,000 shares of the company’s stock in a transaction that occurred on Friday, August 31st. The shares were purchased at an average cost of $5.34 per share, with a total value of $133,500.00. Following the transaction, the director now directly owns 67,895 shares of the company’s stock, valued at approximately $362,559.30. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 14.72% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of LCI. BlackRock Inc. grew its position in Lannett by 9.5% during the 2nd quarter. BlackRock Inc. now owns 4,386,677 shares of the company’s stock worth $59,660,000 after purchasing an additional 381,177 shares during the last quarter. LSV Asset Management boosted its holdings in shares of Lannett by 2.1% in the second quarter. LSV Asset Management now owns 2,100,042 shares of the company’s stock valued at $28,560,000 after acquiring an additional 43,031 shares in the last quarter. Heartland Advisors Inc. boosted its holdings in shares of Lannett by 32.8% in the second quarter. Heartland Advisors Inc. now owns 810,500 shares of the company’s stock valued at $11,023,000 after acquiring an additional 200,000 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Lannett by 36.8% in the first quarter. Northern Trust Corp now owns 800,762 shares of the company’s stock valued at $12,852,000 after acquiring an additional 215,228 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Lannett by 12.1% in the first quarter. Russell Investments Group Ltd. now owns 517,221 shares of the company’s stock valued at $8,302,000 after acquiring an additional 55,764 shares in the last quarter. 97.54% of the stock is currently owned by hedge funds and other institutional investors.
Lannett Company Profile
Lannett Company, Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages.
Featured Story: Trading Strategy Methods for Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.